Table 1 Basic characteristics of inflammatory bowel disease (IBD) and controls subjects (HC)
| Â | IBD | HC | ||||||
|---|---|---|---|---|---|---|---|---|
Total (n = 38) | UC (n = 28) | CD (n = 10) | Total (n = 26) | HC_F (n = 13) | HC_NF (n = 13) | |||
UC_F (n = 14) | UC_NF (n = 14) | CD_F (n = 5) | CD_NF (n = 5) | |||||
Age, Median (range) | 43.0(18–71) | 46.5(27–71) | 44.0(22–62) | 40.0(18–52) | 30.0(27–53) | 42.5(27–54) | 45.0(27–53) | 41.0(29–54) |
Male, n (%) | 22(31.8) | 6(42.9) | 9(64.3) | 4(80.0) | 3(60.0) | 20(32.0) | 12(92.3) | 8(61.5) |
BMI, Median (range) | 24.36(16.16–33.22) | 26.44(25.61–30.30)a | 20.32(16.71–23.53) | 27.28(25.18–33.22)b | 18.37(16.16–19.59) | 24.44(18.61–31.77) | 25.38(25.00–31.77)c | 21.36(18.61–23.88) |
Duration of disease, Median year (range) | 5.0 (3–7) | 4.5 (3–7) | 5.0 (4–7) | 5.0 (3–5) | 5.0 (4–6) |  |  |  |
Disease extent: UC, n | ||||||||
 Proctitis | – | 0 | 0 | – | – | – | – | – |
 Left-sided colitis | – | 5 | 3 | – | – | – | – | – |
 Pancolitis | – | 9 | 11 | – | – | – | – | – |
Disease extent: CD, n | ||||||||
 Ileal | – | – | – | 1 | 2 | – | – | – |
 Colonic | – | – | – | 1 | 1 | – | – | – |
 Ileocolonic | – | – | – | 3 | 2 | – | – | – |
Current IBD medications, n | ||||||||
 5-ASA | - | 14 | 14 | 0 | 0 | – | – | – |
 Corticosteroids | – | 3 | 5 | 0 | 0 | – | – | – |
 Immunomodulators | – | 0 | 0 | 2 | 1 | – | – | – |
 Biologics | – | 0 | 0 | 5 | 5 | – | – | – |